Krystal Biotech Operating Profit Jumps 72%, But Net Income Falls On A Year-Ago Tax Windfall

A one-time $31.4 million tax benefit in 2025 turned a strong quarter into a profit decline, and a $400 million buyback follows.

Share
Krystal Biotech Operating Profit Jumps 72%, But Net Income Falls On A Year-Ago Tax Windfall

Krystal Biotech, which makes gene therapies including the skin-disease treatment VYJUVEK, saw operating income jump 72% to $71.1 million in the third quarter, from $41.4 million a year earlier. Net income still fell to $63.1 million from $79.4 million, because the year-ago quarter carried a $31.4 million tax benefit that did not repeat, the company said in its 10-Q filed Monday.

The tax swing behind the profit drop

Pre-tax income rose $32.2 million, to $80.1 million. But the company booked $17.1 million of income tax expense, against that $31.4 million benefit in the prior-year quarter.

The benefit came from releasing a $48.4 million valuation allowance, a reserve against deferred tax assets, which the filing calls a one-time item. Diluted earnings per share fell to $2.05 from $2.66.

For the first nine months, net income rose to $173.8 million from $153.4 million, while operating income climbed 57%.

Net product revenue rose 30% to $127.3 million, driven by launches in Europe and Japan. Europe contributed $23.3 million and Japan $8.8 million, while U.S. sales edged up to $95.3 million from $92.9 million. Gross margin was 94%.

Selling, general and administrative expense fell $3.8 million, and $3.0 million of that came from insurance proceeds reimbursing litigation legal costs. That line did not appear in the prior quarter's filing.

Krystal is a gene-therapy company whose VYJUVEK is a topical treatment for dystrophic epidermolysis bullosa, a rare skin disease. It is approved in the United States, Europe and Japan.

Buyback against a cash pile

The board authorized a $400 million repurchase program in October. Chairman and CEO Krish S. Krishnan said the company expects to buy shares "opportunistically over the next two years." The program has no expiration date and does not obligate the company to buy any amount.

The 10-Q's risk factors warn that repurchases could reduce cash available for clinical programs and VYJUVEK's commercialization. Cash, equivalents and short-term investments stood at $911.9 million on September 30.

Reserves for rebates, prompt-pay discounts and other accruals reached $98.5 million, up from $68.1 million at year-end, as provisions of $83.3 million outran $52.9 million of payments.

Pipeline dates slip, others arrive

Slow enrollment in the EMERALD-1 eye-drop trial has pushed both finishing enrollment and top-line data to 2027. The cystic fibrosis study's interim results moved to the first half of 2027.

Interim results from HALITE-1 in Hailey-Hailey disease are expected before year-end, and a pricing decision in Spain is also expected before the end of the year. Pricing talks with Italian authorities finished in October, with an Italian launch expected in early 2027.

Krystal expects interim HALITE-1 results before the end of 2026.

Sources

More on Krystal Biotech

All Krystal Biotech (KRYS) coverage →